Latest news

• Positive trial results for Janssen’s Symtuza boosts its HIV credentials

  The STR provided ‘effective’and ‘durable’viral suppression. Janssen’s darunavir-based single tablet regimen (STR) Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) showed a positive outcome in the treatment of HIV

• Janssen wins European approval for Symtuza

  It’s the first complete, single-tablet regimen (STR) based on its big-selling protease inhibitor Prezista (darunavir), which it combines with cobicistat, emtricitabine and tenofovir alafenamide (TAF).

• CHMP backs three immuno-oncology drugs for solid tumours

  The once-daily product combines darunavir with cobicistat, emtricitabine and tenofovir alafenamide (TAF) and is vying to compete with therapies from GlaxoSmithKline's ViiV unit.

• Gilead plans fightback against HIV arch-rival ViiV

  its Genvoya and Stribild products - which needs to be boosted with cobicistat.

• ViiV takes two-drug cocktail for first-line HIV into phase III

  HIV therapies that combine multiple drugs into one tablet such as ViiV's Triumeq (dolutegravir/abacavir/lamivudine) and Gilead's Quad product (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) are expected to be